New Study Suggests that Statins Could Slow the Progression of Alzheimer’s Disease

by

A new study led by Karolinska Institutet has revealed that statins, a type of lipid-lowering medication, may slow down the progression of Alzheimer’s disease in some patients. Published in Alzheimer Research and Therapy, the study found that individuals with Alzheimer’s dementia who were treated with statins displayed a slower deterioration in cognitive functions compared to those who were not treated. However, the researchers caution that the study is observational and cannot establish a causal relationship.

The researchers compared data from a registry, analyzing over 15,500 patients with dementia who also required lipid-lowering treatment. Of these patients, nearly 11,000 were treated with statins. It was observed that those who received statin treatment performed slightly better in cognitive tests, despite having a higher prevalence of risk factors for dementia such as high blood pressure, cardiovascular disease, and diabetes.

However, the results of this study do not provide definitive evidence that individuals with dementia should be treated with statins. Nevertheless, there is also no evidence to suggest that statin treatment should be avoided. Therefore, if a person with high blood lipids requires statins, a dementia diagnosis should not prevent them from receiving treatment, according to Sara Garcia-Ptacek, docent of neuroscience and assistant professor at the Department of Neurobiology, Care Sciences, and Society, who led the research.

Garcia-Ptacek emphasizes the importance of safety due to initial concerns that statins might cause confusion in dementia patients. This has led to some resistance in prescribing these medications to individuals with dementia. However, the findings of this study suggest that such concerns may not be warranted.

The study is a crucial first step in a research journey that aims to determine a causal link between statins and cognition. The researchers envision conducting a more precise cohort study that could eventually lead to a clinical intervention study. This would help identify which patient groups benefit the most from statin treatment and why.

While the idea that statins could impact the risk or progression of dementia is not new, previous clinical studies have yielded negative results. The researchers believe that specific patient groups with Alzheimer’s dementia may benefit from statins, and that previous trials may have been too small to demonstrate significant differences. Therefore, a more targeted approach is necessary to evaluate the benefits of statin treatment in individuals with dementia.

In conclusion, the study suggests that statins may have the potential to slow down the progression of Alzheimer’s disease in some patients. However, further research is required to establish a causal link and determine which patient groups would benefit the most from statin treatment. Nonetheless, the findings provide hope for potential future interventions that could improve the lives of individuals with Alzheimer’s dementia.

Ravina
+ posts

Ravina Pandya,  Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.